- Home
- SBFM vs IDAI Comparison
SBFM vs IDAI Comparison
Compare SBFM & IDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBFM
- IDAI
- Stock Information
- Founded
- SBFM 2006
- IDAI 2016
- Country
- SBFM United States
- IDAI United States
- Employees
- SBFM N/A
- IDAI N/A
- Industry
- SBFM Biotechnology: Pharmaceutical Preparations
- IDAI Computer Software: Prepackaged Software
- Sector
- SBFM Health Care
- IDAI Technology
- Exchange
- SBFM Nasdaq
- IDAI Nasdaq
- Market Cap
- SBFM 6.7M
- IDAI 7.7M
- IPO Year
- SBFM N/A
- IDAI N/A
- Fundamental
- Price
- SBFM $1.67
- IDAI $4.14
- Analyst Decision
- SBFM Strong Buy
- IDAI Strong Buy
- Analyst Count
- SBFM 1
- IDAI 1
- Target Price
- SBFM $7.00
- IDAI $12.00
- AVG Volume (30 Days)
- SBFM 2.2M
- IDAI 260.2K
- Earning Date
- SBFM 11-12-2025
- IDAI 11-07-2025
- Dividend Yield
- SBFM N/A
- IDAI N/A
- EPS Growth
- SBFM N/A
- IDAI N/A
- EPS
- SBFM N/A
- IDAI N/A
- Revenue
- SBFM $36,341,741.00
- IDAI $3,366,415.00
- Revenue This Year
- SBFM $21.12
- IDAI $25.13
- Revenue Next Year
- SBFM $44.89
- IDAI $164.45
- P/E Ratio
- SBFM N/A
- IDAI N/A
- Revenue Growth
- SBFM 19.22
- IDAI N/A
- 52 Week Low
- SBFM $1.17
- IDAI $1.43
- 52 Week High
- SBFM $3.90
- IDAI $18.75
- Technical
- Relative Strength Index (RSI)
- SBFM 45.56
- IDAI 57.59
- Support Level
- SBFM $1.81
- IDAI $4.13
- Resistance Level
- SBFM $2.13
- IDAI $4.58
- Average True Range (ATR)
- SBFM 0.16
- IDAI 0.43
- MACD
- SBFM -0.04
- IDAI 0.01
- Stochastic Oscillator
- SBFM 7.32
- IDAI 50.14
About SBFM Sunshine Biopharma Inc.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.
About IDAI T Stamp Inc.
T Stamp Inc develops and markets identity authentication software solutions for enterprise partners and peer-to-peer markets. The company is engaged in developing proprietary artificial intelligence-powered solutions; researching and leveraging biometric science, cryptography, and data mining to deliver insightful identity & trust predictions while identifying and defending against fraudulent identity attacks, protecting sensitive user information, and extending the reach of digital services through accessibility. The artificial intelligence-powered solutions segment generates revenue principally from software licenses, professional services, and recurring Software-as-a-Service ("SaaS") revenue.